Hugel, a GS Group affiliate, discloses 2025 financials and governance - No material events
Hugel, a GS Group affiliate, reported total assets of 756.8B KRW, total liabilities of 75.8B KRW (debt ratio 11.14%), and total equity of 681.0B KRW as of end-2025.
Sales of 292.9B KRW, operating profit of 106.9B KRW, and net profit of 80.1B KRW, maintaining stable profitability.
Largest shareholder: Aphrodite Acquisition Holdings LLC (43.53%), plus treasury stock 12.20%, total controlling interest 55.72%.
100% control of 10 overseas subsidiaries (Thailand 98%), global sales of botulinum toxin, fillers, and other medical aesthetics products.
Board consists of CEO Jang Doo-hyun and 10 others; routine changes include new outside director (Na Jeong-in) and non-executive director (Julia Carroll Strom).
Intra-group transactions are minor, with major internal transactions being product/service sales to overseas affiliates (approx. 33.4B KRW) and asset leases.
Electronic voting system adopted (general shareholder voting ratio 5.68%) for shareholder rights.
[AI Summary]This disclosure is a routine annual filing of a conglomerate affiliate, with no material changes in financial structure or governance. Solid earnings and low debt ratio are positive, but absence of shareholder return policies or structural catalysts suggests a neutral impact on the stock price.
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]